An Observational Study of XL-184 Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 19 Feb 2018
At a glance
- Drugs Cabozantinib (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- 13 Feb 2018 Planned End Date changed from 8 Jan 2019 to 8 Jan 2021.
- 13 Feb 2018 Planned primary completion date changed from 8 Jan 2019 to 8 Jan 2020.
- 18 Feb 2017 Results presented at the 2017 Genitourinary Cancers Symposium.